Genotypic Effects of the TOMM40′523 Variant and APOE on Longitudinal Cognitive Change over 4 Years: The TOMMORROW Study

dc.contributor.author

Zou, H

dc.contributor.author

Luo, S

dc.contributor.author

Liu, H

dc.contributor.author

Lutz, MW

dc.contributor.author

Bennett, DA

dc.contributor.author

Plassman, BL

dc.contributor.author

Welsh-Bohmer, KA

dc.date.accessioned

2023-10-01T14:17:53Z

dc.date.available

2023-10-01T14:17:53Z

dc.date.issued

2023-01-01

dc.date.updated

2023-10-01T14:17:52Z

dc.description.abstract

Background: The 523 poly-T length polymorphism (rs10524523) in TOMM40 has been reported to influence longitudinal cognitive test performance within APOE ε3/3 carriers. The results from prior studies are inconsistent. It is also unclear whether specific APOE and TOMM40 genotypes contribute to heterogeneity in longitudinal cognitive performance during the preclinical stages of AD. Objectives: To determine the effects of these genes on longitudinal cognitive change in early preclinical stages of AD, we used the clinical trial data from the recently concluded TOMMORROW study to examine the effects of APOE and TOMM40 genotypes on neuropsychological test performance. Design: A phase 3, double-blind, placebo-controlled, randomized clinical trial. Setting: Academic affiliated and private research clinics in Australia, Germany, Switzerland, the UK, and the USA. Participants: Cognitively normal older adults aged 65 to 83. Intervention: Pioglitazone tablet. Measurements: Participants from the TOMMORROW trial were stratified based on APOE genotype (APOE ε3/3, APOE ε3/4, APOE ε4/4). APOE ε3/3 carriers were further stratified by TOMM40′523 genotype. The final analysis dataset consists of 1,330 APOE ε3/3 carriers and 7,001 visits. Linear mixed models were used to compare the rates of decline in cognition across APOE groups and the APOE ε3/3 carriers with different TOMM40′523 genotypes. Results: APOE ε3/4 and APOE ε4/4 genotypes compared with the APOE ε3/3 genotype were associated with worse performance on measures of global cognition, episodic memory, and expressive language. Further, over the four years of observation, the APOE ε3/3 carriers with the TOMM40′523-S/S genotype showed better global cognition and accelerated rates of cognitive decline on tests of global cognition, executive function, and attentional processing compared to APOE ε3/3 carriers with TOMM40′523-S/VL and VL/VL genotypes and compared to the APOE ε3/4 and APOE ε4/4 carriers. Conclusions: We suggest that both APOE and TOMM40 genotypes may independently contribute to cognitive heterogeneity in the pre-MCI stages of AD. Controlling for this genetic variability will be important in clinical trials designed to slow the rate of cognitive decline and/or prevent symptom onset in preclinical AD.

dc.identifier.issn

2274-5807

dc.identifier.issn

2426-0266

dc.identifier.uri

https://hdl.handle.net/10161/29049

dc.publisher

SERDI

dc.relation.ispartof

Journal of Prevention of Alzheimer's Disease

dc.relation.isversionof

10.14283/jpad.2023.115

dc.subject

Alzheimer's disease

dc.subject

TOMM40

dc.subject

APOE

dc.subject

cognitive change

dc.subject

TOMMORROW

dc.title

Genotypic Effects of the TOMM40′523 Variant and APOE on Longitudinal Cognitive Change over 4 Years: The TOMMORROW Study

dc.type

Journal article

duke.contributor.orcid

Zou, H|0000-0002-3595-8716

duke.contributor.orcid

Luo, S|0000-0003-4214-5809

duke.contributor.orcid

Lutz, MW|0000-0001-8809-5574

duke.contributor.orcid

Plassman, BL|0000-0003-2867-7198

duke.contributor.orcid

Welsh-Bohmer, KA|0000-0003-1824-0179

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Trinity College of Arts & Sciences

pubs.organisational-group

Staff

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Pathology

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Psychology & Neuroscience

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Duke Institute for Brain Sciences

pubs.organisational-group

Neurology

pubs.organisational-group

Neurology, Behavioral Neurology

pubs.organisational-group

Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences

pubs.organisational-group

Biostatistics & Bioinformatics, Division of Biostatistics

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023Zou_et_al2023JPAD.pdf
Size:
413.58 KB
Format:
Adobe Portable Document Format
Description:
Published version